Making drugs safer: improving drug delivery and reducing the side effect of drugs on the human biochemical system

Abstract

Abstract Restrategizing becomes inevitable when in trying to proffer solution to a problem, damage in a different form is done. The unintended effects of drugs (side effects) could be leaving behind more damage than the therapeutic effect they are required to provide. This has led to the withdrawal of a number of drugs. However, there are still a number of options to explore in delivery, especially in the application of nanomedicine. Such advances in nanomedicine employ the use of phenylboronic acid-installed polymeric micelles, matrix metalloproteinase 2-sensitive poly(ethylene glycol)-drug conjugate, multifunctional DNA nanoflowers, single vehicular delivery of small interfering RNA (siRNA), nanoparticle-mediated codelivery of siRNA and prodrug, lipopeptide nanoparticles for siRNA delivery, ferrous iron-dependent drug delivery, polyprodrug amphiphiles, transepithelial transport of Fc-targeted nanoparticles, mutant KRAS target, monovalent molecular shuttle, near-infrared-actuated devices, transferrin receptor trafficking, remote loading of preencapsulated drugs, ATP-mediated liposomal drug delivery, nanoparticle-based combination chemotherapy delivery system, nucleic acid nanoparticle conjugates, ultrasound-triggered disruption of cross-linked hydrogels, refilling drug delivery depots through the blood, siRNA payloads to target KRAS-mutant cancer, delivery of antibody mimics into mammalian cells, biologically “smart” hydrogel, combination of liposomes containing bio-enhancers, and tetraether lipids. Minimized side effects, increased bioavailability, and reduced dosage are possible benefits of improved drug targeting.